Gene expression regulatory system using crispr system
AssigneeGenkore Inc.
InventorsYong-Sam KIM, Do Yon KIM, Hyun Jung CHIN, Dongmin JEONG, Jeong Heon KO
Life of this patent
Estimating the term…
Abstract
A CRISPR regulatory system is disclosed. More particularly, the CRISPR regulatory system is useful for effectively regulating expression of a target gene and contains a Cas12f1 fusion protein and an engineered Cas12f1 guide RNA Uses of the CRISPR regulatory system are also disclosed. A method of regulating expression of a target gene by using a CRISPR regulatory system containing a Cas12f1 fusion protein and an engineered Cas12f1 guide RNA is also disclosed.
Claims22
A gene expression regulatory composition for inhibiting expression of a target gene, the composition comprising:
- a transcriptional inhibitor Cas12f1 fusion protein or a nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein, and
- an engineered Cas12f1 guide RNA or a nucleic acid encoding the engineered Cas12f1 guide RNA,
- wherein the transcriptional inhibitor Cas12f1 fusion protein comprises a dead Cas12f1 (dCas12f1) protein and a transcriptional inhibitor protein,
- wherein the dCas12f1 protein is a modified form of a wild-type Cas12f1 protein in which aspartic acid (D) which is the 326th amino acid, glutamic acid (E) which is the 422nd amino acid, arginine (R) which is the 490th amino acid, or aspartic acid (D) which is the 510th amino acid in the amino acid sequence constituting the wild-type Cas12f1 protein is substituted with alanine (A), glutamine (Q), leucine (L), tryptophan (W), or valine (V), and
- the transcriptional inhibitor protein is a protein or peptide that inhibits or suppresses transcription of the gene, and
- wherein the engineered Cas12f1 guide RNA comprises:
- an engineered scaffold region;
- a spacer, and
- a U-rich tail,
- wherein the engineered scaffold region, the spacer, and the U-rich tail are sequentially linked to each other in a 5′ to 3′ direction,
- the spacer comprises 10 to 50 nucleotides, and has a sequence complementary to the target sequence,
- a sequence of the U-rich tail is represented by (UaN)bUc, wherein N is one of adenosine (A), uridine (U), cytidine (C), and guanosine (G), and a, b, c are each an integer, with a being between 1 to 5 inclusive, and b being 0 or greater,
- a sequence of the engineered scaffold region is different from 5′-CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGA ACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCUU CGGAAAGUAACCCUCGAAACCAAAUUCAUUUGAAAGAAUGAAGGAAUGCAAC-3′ (SEQ ID NO:
- 7), and
- the sequence of the engineered scaffold region is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
- a sequence selected from the group consisting of 5′-A-3′, 5′-AA-3′, 5′-GAA-3′, 5′-AGAA-3′, 5′-GAGAA-3′, 5′-GGAGAA-3′, 5′-UGGAGAA-3′, 5′-GUGGAGAA-3′, 5′-AGUGGAGAA-3′, 5′-AAGUGGAGAA-3′ (SEQ ID NO:
- 17), 5′-AAAGUGGAGAA-3′ (SEQ ID NO:
- 18),
- 5′-UAAAGUGGAGAA-3′ (SEQ ID NO:
- 19),
- 5′-AUAAAGUGGAGAA-3′ (SEQ ID NO:
- 20),
- 5′-GAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 21),
- 5′-UGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 22),
- 5′-CUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 23),
- 5′-ACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 24),
- 5′-CACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 25),
- 5′-UCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 26),
- 5′-UUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 27), and
- 5′-CUUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 10);
- a sequence selected from the group consisting of 5′-G-3′, 5′-UUAGG-3′, 5′-CUUAGGG-3′, 5′-CUUAGUGG-3′, 5′-CCUUAGGUGG-3′ (SEQ ID NO:
- 342), 5′-CCGUUAGGUGG-3′ (SEQ ID NO:
- 343), 5′-CCGCUUAGGGUGG-3′ (SEQ ID NO:
- 344),
- 5′-CCGCUUUAGAGGUGG-3′ (SEQ ID NO:
- 345),
- 5′-CCGCUUUUAGAAGGUGG-3′ (SEQ ID NO:
- 346),
- 5′-CCGCUUCUUAGGAAGGUGG-3′ (SEQ ID NO:
- 347),
- 5′-CCGCUUCAUUAGUGAAGGUGG-3′ (SEQ ID NO:
- 348),
- 5′-CCGCUUCACUUAGGUGAAGGUGG-3′ (SEQ ID NO:
- 349),
- 5′-CCGCUUCACUUAGAGUGAAGGUGG-3′ (SEQ ID NO:
- 350),
- 5′-CCGCUUCACCUUAGGAGUGAAGGUGG-3′ (SEQ ID NO:
- 351),
- 5′-CCGCUUCACCAUUAGUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 352),
- 5′-CCGCUUCACCAAUUAGUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 353),
- 5′-CCGCUUCACCAAAUUAGCUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 354),
- 5′-CCGCUUCACCAAAAUUAGACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 355),
- 5′-CCGCUUCACCAAAAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 356),
- 5′-CCGCUUCACCAAAAGCUUAGGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 357),
- 5′-CCGCUUCACCAAAAGCUUUAGAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 358),
- 5′-CCGCUUCACCAAAAGCUGUUAGUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 359),
- 5′-CCGCUUCACCAAAAGCUGUUAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 360),
- 5′-CCGCUUCACCAAAAGCUGUUUAGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 361),
- 5′-CCGCUUCACCAAAAGCUGUCUUAGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 362), and
- 5′-CCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 11);
- a sequence selected from the group consisting of 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 434),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUUCGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 435),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCGAAGUAACCCUCGA-3′ (SEQ ID NO:
- 436),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUCUUCGGAGUAACCCUCGA-3′ (SEQ ID NO:
- 437),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCGAGUAACCCUCGA-3′ (SEQ ID NO:
- 438),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUCGGUAACCCUCGA-3′ (SEQ ID NO:
- 439),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGUUCGUAACCCUCGA-3′ (SEQ ID NO:
- 440),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUUCGAACCCUCGA-3′ (SEQ ID NO:
- 441),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGACCCUCGA-3′ (SEQ ID NO:
- 442),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGCCCUCGA-3′ (SEQ ID NO:
- 443),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCCUCGA-3′ (SEQ ID NO:
- 444),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCUCGA-3′ (SEQ ID NO:
- 445),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAUUCGCCUCGA-3′ (SEQ ID NO:
- 446),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGUUCGCUCGA-3′ (SEQ ID NO:
- 447), and
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 12);
- a sequence selected from 5′-AACAAAGAAAGGA-3′ (SEQ ID NO:
- 111),
- 5′-AACAAAUGAAAAGGA-3′ (SEQ ID NO:
- 112),
- 5′-AACAAAUUGAAAAAGGA-3′ (SEQ ID NO:
- 113),
- 5′-AACAAAUUCGAAAGAAGGA-3′ (SEQ ID NO:
- 114),
- 5′-AACAAAUUCAGAAAUGAAGGA-3′ (SEQ ID NO:
- 115),
- 5′-AACAAAUUCAUGAAAAUGAAGGA-3′ (SEQ ID NO:
- 116),
- 5′-AACAAAUUCAUUGAAAAAUGAAGGA-3′ (SEQ ID NO:
- 117), and
- 5′-AACAAAUUCAUUUGAAAGAAUGAAGGA-3′ (SEQ ID NO:
- 118);
- and
- 5′-AUGCAAC-3′.
A method of inhibiting expression of a target gene in a cell, the method comprising
- delivering, into a cell, a transcriptional inhibitor Cas12f1 fusion protein or a nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein, and an engineered Cas12f1 guide RNA or a nucleic acid encoding the engineered Cas12f1 guide RNA,
- which allows a CRISPR interference complex to be formed in the cell,
- wherein the CRISPR interference complex is capable of suppressing transcription of the target gene,
- the transcriptional inhibitor Cas12f1 fusion protein comprises a dead Cas12f1 (dCas12f1) protein and a transcriptional inhibitor protein,
- the dCas12f1 protein is a modified form of a wild-type Cas12f1 protein in which aspartic acid (D) which is the 326th amino acid, glutamic acid (E) which is the 422nd amino acid, arginine (R) which is the 490th amino acid, or aspartic acid (D) which is the 510th amino acid in the amino acid sequence constituting the wild-type Cas12f1 protein is substituted with alanine (A), glutamine (Q), leucine (L), tryptophan (W), or valine (V), and
- the transcriptional inhibitor protein is a protein or peptide that inhibits or suppresses transcription of the gene, and
- wherein the engineered Cas12f1 guide RNA comprises:
- an engineered scaffold region;
- a spacer, and
- a U-rich tail,
- wherein the engineered scaffold region, the spacer, and the U-rich tail are sequentially linked to each other in a 5′ to 3′ direction,
- the spacer comprises 10 to 50 nucleotides, and has a sequence complementary to the target sequence,
- a sequence of the U-rich tail is represented by (UaN)bUc, wherein N is one of adenosine (A), uridine (U), cytidine (C), and guanosine (G), and a, b, c are each an integer, with a being between 1 to 5 inclusive, and b being 0 or greater,
- a sequence of the engineered scaffold region is different from 5′-CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGA ACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCUU CGGAAAGUAACCCUCGAAACCAAAUUCAUUUGAAAGAAUGAAGGAAUGCAAC-3′ (SEQ ID NO:
- 7), and
- the sequence of the engineered scaffold region is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
- a sequence selected from the group consisting of 5′-A-3′, 5′-AA-3′, 5′-GAA-3′, 5′-AGAA-3′, 5′-GAGAA-3′, 5′-GGAGAA-3′, 5′-UGGAGAA-3′, 5′-GUGGAGAA-3′, 5′-AGUGGAGAA-3′, 5′-AAGUGGAGAA-3′ (SEQ ID NO:
- 17), 5′-AAAGUGGAGAA-3′ (SEQ ID NO:
- 18),
- 5′-UAAAGUGGAGAA-3′ (SEQ ID NO:
- 19),
- 5′-AUAAAGUGGAGAA-3′ (SEQ ID NO:
- 20),
- 5′-GAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 21),
- 5′-UGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 22),
- 5′-CUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 23),
- 5′-ACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 24),
- 5′-CACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 25),
- 5′-UCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 26),
- 5′-UUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 27), and
- 5′-CUUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO:
- 10);
- a sequence selected from the group consisting of 5′-G-3′, 5′-UUAGG-3′, 5′-CUUAGGG-3′, 5′-CUUAGUGG-3′, 5′-CCUUAGGUGG-3′ (SEQ ID NO:
- 342), 5′-CCGUUAGGUGG-3′ (SEQ ID NO:
- 343), 5′-CCGCUUAGGGUGG-3′ (SEQ ID NO:
- 344),
- 5′-CCGCUUUAGAGGUGG-3′ (SEQ ID NO:
- 345),
- 5′-CCGCUUUUAGAAGGUGG-3′ (SEQ ID NO:
- 346),
- 5′-CCGCUUCUUAGGAAGGUGG-3′ (SEQ ID NO:
- 347),
- 5′-CCGCUUCAUUAGUGAAGGUGG-3′ (SEQ ID NO:
- 348),
- 5′-CCGCUUCACUUAGGUGAAGGUGG-3′ (SEQ ID NO:
- 349),
- 5′-CCGCUUCACUUAGAGUGAAGGUGG-3′ (SEQ ID NO:
- 350),
- 5′-CCGCUUCACCUUAGGAGUGAAGGUGG-3′ (SEQ ID NO:
- 351),
- 5′-CCGCUUCACCAUUAGUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 352),
- 5′-CCGCUUCACCAAUUAGUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 353),
- 5′-CCGCUUCACCAAAUUAGCUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 354),
- 5′-CCGCUUCACCAAAAUUAGACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 355),
- 5′-CCGCUUCACCAAAAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 356),
- 5′-CCGCUUCACCAAAAGCUUAGGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 357),
- 5′-CCGCUUCACCAAAAGCUUUAGAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 358),
- 5′-CCGCUUCACCAAAAGCUGUUAGUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 359),
- 5′-CCGCUUCACCAAAAGCUGUUAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 360),
- 5′-CCGCUUCACCAAAAGCUGUUUAGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 361),
- 5′-CCGCUUCACCAAAAGCUGUCUUAGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 362), and
- 5′-CCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO:
- 11);
- a sequence selected from the group consisting of 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 434),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUUCGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 435),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCGAAGUAACCCUCGA-3′ (SEQ ID NO:
- 436),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUCUUCGGAGUAACCCUCGA-3′ (SEQ ID NO:
- 437),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCGAGUAACCCUCGA-3′ (SEQ ID NO:
- 438),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUCGGUAACCCUCGA-3′ (SEQ ID NO:
- 439),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGUUCGUAACCCUCGA-3′ (SEQ ID NO:
- 440),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUUCGAACCCUCGA-3′ (SEQ ID NO:
- 441),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGACCCUCGA-3′ (SEQ ID NO:
- 442),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGCCCUCGA-3′ (SEQ ID NO:
- 443),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCCUCGA-3′ (SEQ ID NO:
- 444),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCUCGA-3′ (SEQ ID NO:
- 445),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAUUCGCCUCGA-3′ (SEQ ID NO:
- 446),
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGUUCGCUCGA-3′ (SEQ ID NO:
- 447), and
- 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO:
- 12);
- a sequence selected from 5′-AACAAAGAAAGGA-3′ (SEQ ID NO:
- 111),
- 5′-AACAAAUGAAAAGGA-3′ (SEQ ID NO:
- 112),
- 5′-AACAAAUUGAAAAAGGA-3′ (SEQ ID NO:
- 113),
- 5′-AACAAAUUCGAAAGAAGGA-3′ (SEQ ID NO:
- 114),
- 5′-AACAAAUUCAGAAAUGAAGGA-3′ (SEQ ID NO:
- 115),
- 5′-AACAAAUUCAUGAAAAUGAAGGA-3′ (SEQ ID NO:
- 116),
- 5′-AACAAAUUCAUUGAAAAAUGAAGGA-3′ (SEQ ID NO:
- 117), and
- 5′-AACAAAUUCAUUUGAAAGAAUGAAGGA-3′ (SEQ ID NO:
- 118);
- and
- 5′-AUGCAAC-3′.
Dependencies are inferred from the claim text.